Acute lymphocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The past decade has witnessed tremendous progress in the treatment of acute lymphoblastic leukaemia (ALL), primarily due to the development of targeted therapies, including tyrosine kinase inhibitors targeting BCR-ABL1 tyrosine kinase, monoclonal antibodies targeting cell surface antigens (CD19, CD20 and CD22), bispecific antibodies and chimeric antigen receptor T- cell therapy.
|
31566728 |
2020 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
There have been successful examples of targeted therapy improving the outcome of some childhood cancers, such as the addition of an ABL class tyrosine kinase inhibitor to conventional chemotherapy substantially improving the cure rate for patients with BCR-ABL1 positive acute lymphoblastic leukemia.
|
31563145 |
2020 |
Acute lymphocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of the total 631 cases, 52.9% (n=334) were acute lymphoblastic leukemia (ALL), 43.9% (n=277) acute myeloid leukemia (AML), 2.2% (n=14) mixed phenotypic acute leukemia (MPAL), 0.5% (n=3) acute undifferentiated leukemia (AUL) and 0.5% (n=3) chronic myeloid leukemia in blast crisis (CML-BC).
|
30858955 |
2019 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
There are different BCR-ABL1 fusion genes that are translated into proteins that are different from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute lymphoblastic leukemia.
|
30675008 |
2019 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular detection of the <i>BCR-ABL1</i> fusion transcripts is necessary for the genetic confirmation of a chronic myeloid leukemia diagnosis and for the risk classification of acute lymphoblastic leukemia.
|
31817063 |
2019 |
Acute lymphocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
At the 60<sup>th</sup> month, estimated CBMR and CEMR incidences were, respectively, 14.3 (5.1)% and 25.9 (6.6)% in ALL, 25.8 (5.9)% and 15.5 (4.8)% in AML, and 61.5 (16.5)% and 17.9 (13.4)% in CML.
|
30116013 |
2019 |
Acute lymphocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We searched for original articles and reviews describing the pharmacology and clinical use of dasatinib in ALL with BCR-ABL1.
|
30916583 |
2019 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
At current work, the combination of sensors were used to detect the presence of BCR-ABL1 as a mutant gene and CEA as a biomarkers of cancer, such a capability makes the package liable for early and certain detection of acute lymphoblastic leukemia.
|
31295447 |
2019 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification and characterization of a murine model of BCR‑ABL1+ acute B‑lymphoblastic leukemia with central nervous system metastasis.
|
31173268 |
2019 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCR-ABL1 signal patterns were analyzed using FISH in 243 CML-chronic phase (CML-CP), 17 CML-blast phase (CML-BP) and 52 BCR-ABL1 positive acute lymphoblastic leukemia (ALL) patients.
|
31594548 |
2019 |
Acute lymphocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Four patients presented with B-lymphoblastic leukemia (B-ALL), and of them, two patients with t(8;9)(p22;p24.1) were proven to be B-lymphoblastic crisis of MPN; and the other two cases with t(9p24;v) both were de novo B-ALL, BCR-ABL1-like (Ph-like).
|
30401948 |
2019 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
An 11-year-old male patient with the deletion of <i>IKZF1</i> (Ikaros family zinc finger 1) and positive Breakpoint Cluster Region-C-Abelson oncogene 1(<i>BCR-ABL1</i>) acute lymphoblastic leukemia developed mucositis, gastrointestinal toxicity, hepatotoxicity, myelosuppression, and severe dermatologic toxicity during the first and second courses of high-dose methotrexate.
|
31607921 |
2019 |
Acute lymphocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To date, no case reports of a patient diagnosed with CML BC presented with Ph chromosome-positive AML mimicking ALL have been reported.
|
31218758 |
2019 |
Acute lymphocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our B-ALL fluorescence in situ hybridization (FISH) panel confirmed the BCR/ABL1 fusion and monosomies consistent with chromosome studies in approximately 95% of interphase nuclei.
|
30790375 |
2019 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This case illustrates the major interest of interphase FISH for BCR-ABL1 rearrangement on blood neutrophils as a decisive method to discriminate a lymphoid blast crisis of CML from a de novo BCR-ABL1 positive ALL.
|
28444777 |
2018 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pediatric ALL had higher prevalence of ETV6-RUNX1, TCF3-PBX1, and STIL-TAL1, while BCR-ABL1 and SET-NUP214 were more common in adult ALL.
|
30125757 |
2018 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCR/ABL1-like acute lymphoblastic leukaemia (ALL) is a subgroup of B-lineage acute lymphoblastic leukaemia that occurs within cases without recurrent molecular rearrangements.
|
29675955 |
2018 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
|
28579617 |
2018 |
Acute lymphocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CD25 (IL-2RA) and CD26 (DPPIV) were expressed on LSCs in Ph<sup>+</sup> ALL exhibiting BCR/ABL1<sub>p210</sub>, whereas in Ph<sup>+</sup> ALL with BCR/ABL1<sub>p190</sub>, LSCs variably expressed CD25 but did not express CD26.
|
29772458 |
2018 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
E14a3 breakpoint cluster region (BCR)/ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL) fusion transcript is rare in Philadelphia chromosome positive disease, particularly in acute lymphoblastic leukemia (ALL).
|
29434963 |
2018 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>IKZF1</i> gene defects are associated with inferior treatment outcome in both childhood and adult B-cell precursor acute lymphoblastic leukemia and occur in more than 70% of <i>BCR-ABL1</i>-positive and <i>BCR-ABL1</i>-like cases of acute lymphoblastic leukemia.
|
29519871 |
2018 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phosphatase of regenerating liver-3 <i>(PRL-3/PTP4A3)</i> is upregulated in multiple cancers, including BCR-ABL1- and ETV6-RUNX-positive acute lymphoblastic leukemia (ALL).
|
29423065 |
2018 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To our knowledge, this is the first successful use of nilotinib in BCR-ABL1-like phenotype ALL.
|
30121665 |
2018 |
Acute lymphocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To address this, we studied 142 adults with ALL treated with hyperCVAD over a 10-year period who had MRD assessed by either multi-parameter flow cytometry or (for patients with Philadelphia chromosome positive ALL) reverse transcriptase polymerase chain reaction for the BCR-ABL1 translocation.
|
29318644 |
2018 |
Acute lymphocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The breakpoint cluster region-ABL proto-oncogene 1 (<i>BCR-ABL</i>) rearrangement leads to a p210 chimeric protein in typical chronic myeloid leukemia (CML), whereas 17-25% of patients with acute lymphocytic leukemia and 0.9-3% patients with <i>de novo</i> acute myeloid leukemia (AML) carry a p190<sup>BCR-ABL</sup> fusion protein.
|
29151902 |
2017 |